The Effect of Rivaroxaban in Sickle Cell Disease
Information source: University of North Carolina, Chapel Hill
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Sickle Cell Anemia; Sickle Cell-beta^0^-Thalassemia
Intervention: rivaroxaban (Drug); placebo (Drug)
Phase: Phase 2
Status: Enrolling by invitation
Sponsored by: University of North Carolina, Chapel Hill Official(s) and/or principal investigator(s): Kenneth I Ataga, MBBS, Principal Investigator, Affiliation: University of North Carolina, Chapel Hill
Summary
The primary study hypothesis is that inhibition of factor Xa with rivaroxaban will reduce
inflammation, coagulation and endothelial cell activation, and improve microvascular blood
flow in patients with sickle cell disease (SCD) during the non-crisis, steady state. To test
this hypothesis, this study will evaluate the effects of rivaroxaban on:
- plasma markers of inflammation;
- plasma markers of endothelial activation;
- plasma markers of thrombin generation; and
- microvascular blood flow assessed using laser Doppler velocimetry (LDV) of
post-occlusive reactive hyperemia (PORH).
In a cross-over design, subjects will receive rivaroxaban 20 mg/day and placebo for 4 weeks
each, separated by a 2-week washout phase.
Clinical Details
Official title: The Effect of Factor Xa Inhibition, With Rivaroxaban, on the Pathology of Sickle Cell Disease
Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Primary outcome: Change from baseline to 4 weeks in soluble vascular cell adhesion molecule-1 (VCAM-1) and interleukin-6 (IL-6)
Secondary outcome: Change from Baseline to Week 4 in other plasma markers of inflammation.Change from baseline to Week 4 in other markers of endothelial cell (EC) activation. Change from baseline to Week 4 in microvascular blood flow Change from baseline to Week 4 in markers of coagulation activation.
Detailed description:
The study will consist of a Screening Phase, two Treatment Phases, a Wash-Out Phase, and a
Follow-up Phase. The Screening Phase will occur within 28 days of randomization and will
include informed consent, a physical examination, and complete medical history to include
determination of sickle cell genotype and current medications. Clinical laboratory tests to
be performed include: a Complete Blood Count (CBC) with differential and reticulocyte count;
Prothrombin time(PT) / activated partial thromboplastin time (aPTT); and serum chemistries
(BUN, creatinine, total and direct bilirubin, alanine aminotransferase (ALT), aspartate
aminotransferase (AST), alkaline phosphatase, and LDH). A chest x-ray and MRI/MRA of the
brain will also be done at Screening to rule out underlying disease.
If the patient is found through the screening process to be eligible, the 1st Treatment
Phase begins. Baseline safety assessments and measurement of biomarkers are completed, then
the subject is randomized to receive rivaroxaban or placebo. After 4 weeks of treatment,
there is a 2-Week Wash-Out Phase. After the Wash-Out Phase, another set of baseline studies
are performed and the 2nd Treatment Phase begins. For this Phase of the study, the subject
"crosses over" to receive whatever treatment - rivaroxaban or placebo - that they did not
receive in the 1st Treatment Phase. After taking the assigned study drug for 4 weeks, the
2nd Treatment Phase ends. The subject returns 2 weeks after the last dose of study treatment
for the Follow-Up Phase, consisting of a single end-of-study visit during which safety
assessments are repeated.
Eligibility
Minimum age: 18 Years.
Maximum age: 55 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- 18 to 55 years of age; sickle cell anemia (HbSS) or sickle-beta0 (HbSβ0) thalassemia;
- serum creatinine ≤ 1. 0 mg/dL men) or 1. 2 mg/dL (women);
- ALT < 2 times upper limits of normal;
- platelet count ≥ 50,000 cu/mm;
- normal baseline PT/international normalized ratio (INR) and aPTT;
- be in the non-crisis, "steady state" with no severe pain episodes during the
preceding 4 weeks;
- ability to understand the requirements of the study and be willing to give informed
consent;
- women of childbearing age must be practicing an adequate method of contraception;
- and if on hydroxyurea, be on a stable dose for at least 3 months prior to enrollment.
Exclusion Criteria:
- hypersensitivity to any component of rivaroxaban;
- history of major GI bleeding or bleeding diathesis;
- baseline Hb < 6. 0 gm/dL;
- history of clinically overt stroke;
- brain magnetic resonance imaging with angiography (MRI/MRA) scan with evidence of
Moya Moya;
- pregnant or breastfeeding;
- active liver disease or ALT > 3 times upper limit of normal;
- on chronic anticoagulant, non-steroidal anti-inflammatory (NSAID) or statin therapy;
- history of metastatic cancer;
- current alcohol abuse;
- on a chronic transfusion program or any blood transfusion in the 3 months prior to
enrollment;
- ingested any investigational drugs within the past 4 weeks.
Locations and Contacts
University of North Carolina - Chapel Hill, Chapel Hill, North Carolina 27599, United States
Additional Information
Starting date: February 2014
Last updated: September 4, 2014
|